Eliminating the guess work in ablation therapy
Real time Predictive visualization of true ablation damage
Real-time ablation. Visualized.
The world’s first and only image analysis system that predicts and visualizes the 24-hour post-treatment ablation morphology in real-time
Allowing physicians to see where they have previously been blind
BioTrace™ interfaces with commercial ultrasound imaging systems to track the tissue’s unique “biological signature” when responding to heat during thermal ablation. This signature is used to predict and visualize the post 24-hour thermal effect in real-time, optimizing the surgeon’s level of control and accuracy during the procedure, to minimize healthy tissue damage and maximize target tissue ablation.

Providing vision. Optimizing results.
A must have system for optimal ablation
Reduced recurrence rates
Maximize efficacy and minimize leftover pathologies
Increased safety
Prevent sever injuries due to overtreatment
Cost effective
No hardware necessary
Quick & easy to adopt
No change to existing surgical procedures
Case Studies
One real-time image is better than a thousand simulations
-
CASE 01
- 61 Year-Old Patient
- RFA Ablation
- Tumor Size 1.8 cm
- Liver Segment #3
- Ablation time: 3 min
92%
BioTrace™ accuracy
compared with 24h post CECT
92%
BioTrace™ accuracy
compared with 24h post CECT
-
CASE 02
- 58 Year-old Patient
- RFA Ablation
- Tumor Size 2.2 cm
- Liver Segment #6
- Ablation time: 2.4min
91% BioTrace™ accuracy
compared with 24h post CECT
91% BioTrace™ accuracy
compared with 24h post CECT
-
CASE 03
- 63 Year-old Patient
- MW Ablation
- Tumor Size 1.5 cm
- Liver segment #4
- Ablation time: 2min
90% BioTrace™ accuracy
compared with 24h post CECT
90% BioTrace™ accuracy
compared with 24h post CECT
Transforming ablation treatments into guided precision therapies
Current Application
Oncology Liver tumor ablation
Advancing thermal ablation into the first line treatment option for tumor removal
Pipeline
Cardiovascular
Transitioning from complicated guess-work into precise, real-time feedback dependent treatments
Pain management
Dramatically increase safety in high-risk nerve-ablation procedures
Team








Board of Directors
Chairman of the Board
Mr. Arie Rosenfeld
Former President & CEO,
Scitex Corp
Director
MR. YOSSI ABU
Founder & CEO, TechsoMed
Director
Mr. Eiji KAKIUCHI
Chairman,
SCREEN Holdings
Director
Mr. Tamir Meiri
Senior Manager,
JJDC, Inc
Director
Mr. Fred Shane
Managing Partner,
Axil Capital
Director
Mr. David Hankin
CEO, AMIT-Technion
Partnerships
Investors






Partners







Clinical



Contact Us
Contact info
TechsoMed
Tel | +972-8-6198866
Email | info@techsomed.com
Meir Weisgal 2, Rehovot, Israel
Website by Pearlcom.co.il